CLVS Clovis Oncology


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
AgricultureCleanClimateClimate ChangeEcologyEmissionEnvironmentEnvironmentalExtreme WeatherGreenhouse Gas EmissionHazardIntensityMaterialsNatural ResourcesNatureNuclearOffsetPackagePackagingPandemicRaw MaterialsWasteWaterAccessBenefitsBlackCalifornia Consumer Privacy ActCharitableCollective BargainingCommunityCultureCustomerCyberCyber SecurityCybersecurityData PrivacyData SecurityDeathDemographicsDisabilityDiversityDrug PricingEmployeeEmployee RetentionEngagementEthnicGenderGeneral Data Protection RegulationHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesHuman RightsIncidentInjuryLabor StandardsPay EquityPerquisitesPrivacyRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSexual HarassmentSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkforceAnti-corruptionAssessmentAssuranceAttorneys GeneralAuditBonusBribeBriberyChronicClass Action LawsuitClassifiedClawbackCommitmentConflict of InterestControversyCorporate GovernanceCorporate PurposeCorruptionDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentIndependent ChairInnovationInnovativeInvestigationLawsuitLeadershipLitigationLong-termMajorityOverseeOversightPerquisitePlaintiffPledgingProcurementPurposeQuality StandardR&DRecoupReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationSpecial MeetingStrategySustainabilitySustainableTargetsTaxTenureTransparencyVoting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The Annual Meeting of Stockholders of the Company was held on June 10, 2021. At the Annual Meeting, the stockholders of the Company voted on the following six proposals and cast their votes as described below. The Annual Meeting was partially adjourned to June 23, 2021 solely with respect to the voting on Proposal Two. The Annual Meeting will resume with respect to Proposal Two at 8:30 a.m. Mountain Time on June 23, 2021 and will continue to be held at the St. Julien Hotel, 900 Walnut Street, Boulder, Colorado 80302.

Proposal One

The individuals listed below were elected at the Annual Meeting to serve a three-year term on the Company’s Board of Directors.

ForWithheldBroker Non-Votes
Patrick J. Mahaffy27,489,14810,652,60633,208,220
Robert W. Azelby26,162,96411,978,79033,208,220
Thorlef Spickschen28,183,4229,958,33233,208,220

- 2 -

Proposal Two

Proposal two was to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock authorized for issuance by the Company from 200,000,000 to 250,000,000. The Company has adjourned the Annual Meeting solely with respect to Proposal Two to provide its stockholders additional time to vote on Proposal Two. Support for Proposal Two has exceeded 67.8% of the votes cast on the proposal. However, the affirmative vote of holders of more than 50% of all of the Company’s issued and outstanding shares of common stock is necessary for Proposal Two to be approved.

Proposal Three

Proposal three was to approve an amendment and restatement of the Clovis Oncology, Inc. 2020 Stock Incentive Plan, as described in the proxy materials. This proposal was approved.

ForAgainstAbstainedBroker Non-Votes

Proposal Four

Proposal four was to approve the Clovis Oncology, Inc. 2021 Employee Stock Purchase Plan, as described in the proxy materials. This proposal was approved.

ForAgainstAbstainedBroker Non-Votes

Proposal Five

Proposal five was to hold an advisory vote on the compensation of the Company’s named executive officers, as described in the proxy materials. This proposal was approved.

ForAgainstAbstainedBroker Non-Votes

Proposal Six

Proposal six was to ratify the appointment of Ernst & Young LLP as auditors of the Company for the fiscal year ending December 31, 2021, as described in the proxy materials. This proposal was approved.

ForAgainstAbstainedBroker Non-Votes